Generali Asset Management SPA SGR Makes New Investment in Qiagen N.V. $QGEN

Generali Asset Management SPA SGR acquired a new stake in shares of Qiagen N.V. (NYSE:QGEN) in the 3rd quarter, Holdings Channel reports. The firm acquired 53,358 shares of the company’s stock, valued at approximately $2,335,000.

Several other institutional investors have also bought and sold shares of QGEN. Amundi grew its stake in shares of Qiagen by 12.4% in the 1st quarter. Amundi now owns 4,757,681 shares of the company’s stock worth $190,498,000 after buying an additional 524,959 shares in the last quarter. State Street Corp increased its holdings in shares of Qiagen by 4.5% in the 2nd quarter. State Street Corp now owns 2,183,206 shares of the company’s stock worth $85,363,000 after buying an additional 93,575 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Qiagen by 20.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,665,011 shares of the company’s stock valued at $66,649,000 after buying an additional 286,665 shares in the last quarter. Swiss National Bank raised its position in shares of Qiagen by 21.1% during the 1st quarter. Swiss National Bank now owns 716,059 shares of the company’s stock valued at $28,686,000 after buying an additional 124,920 shares in the last quarter. Finally, Arbejdsmarkedets Tillaegspension raised its position in shares of Qiagen by 24.8% during the 1st quarter. Arbejdsmarkedets Tillaegspension now owns 636,918 shares of the company’s stock valued at $25,502,000 after buying an additional 126,405 shares in the last quarter. Institutional investors own 70.00% of the company’s stock.

Qiagen Stock Up 0.1%

Shares of NYSE QGEN opened at $50.38 on Friday. Qiagen N.V. has a 1 year low of $32.53 and a 1 year high of $57.81. The firm has a 50-day simple moving average of $45.01 and a two-hundred day simple moving average of $42.72. The company has a market cap of $10.38 billion, a P/E ratio of 25.81, a PEG ratio of 5.00 and a beta of 0.61. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.85 and a quick ratio of 2.31.

Qiagen (NYSE:QGEN) last released its earnings results on Wednesday, August 5th. The company reported $0.62 EPS for the quarter, beating analysts’ consensus estimates of $0.60 by $0.02. The firm had revenue of $535.04 million for the quarter, compared to analysts’ expectations of $527.50 million. Qiagen had a return on equity of 14.47% and a net margin of 19.49%. The company’s quarterly revenue was up .2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.60 earnings per share. Qiagen has set its FY 2026 guidance at 2.430- EPS. Research analysts anticipate that Qiagen N.V. will post 2.44 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts recently commented on QGEN shares. Barclays lowered Qiagen from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $55.00 to $53.00 in a research report on Wednesday. TD Cowen restated a “hold” rating on shares of Qiagen in a research report on Wednesday, July 15th. Morgan Stanley reaffirmed an “overweight” rating on shares of Qiagen in a research note on Friday, September 11th. DZ Bank lowered Qiagen from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 22nd. Finally, Weiss Ratings upgraded Qiagen from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, September 11th. Four research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $46.09.

Qiagen Company Profile

QIAGEN N.V. (NYSE:QGEN) is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials.

Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables.